Takeda to divest four diabetes products in japan to teijin pharma limited

Osaka, japan--(business wire)--takeda pharmaceutical company limited (tokyo:4502) (nyse:tak) (“takeda”) today announced that it has entered into an agreement to transfer the assets, marketing rights and, eventually, marketing authorization associated with a portfolio of select non-core products in japan to teijin pharma limited (“teijin pharma”), a tokyo-based pharmaceutical company, for jpy 133.0 billion, subject to customary legal and regulatory closing conditions. the portfolio to be diveste
TAK Ratings Summary
TAK Quant Ranking